Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$56.63 USD

56.63
1,048,495

+0.68 (1.22%)

Updated Jun 26, 2024 04:00 PM ET

After-Market: $56.62 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $126.55, marking a +0.52% move from the previous day.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.

Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates

The biotech sector was in focus last week with regulatory updates from Bristol Myers (BMY), among others.

Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership

Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Why the National Debt is Irrelevant: John Oliver is Funnier, But We Reach Same Conclusion

Old crystal balls for viewing fiscal discipline never foresaw this golden age of tech innovation and ultra-low inflation.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $114.60 in the latest trading session, marking a -0.82% move from the prior day.

Kevin Cook headshot

Bear of the Day: Gold Fields (GFI)

Miners continue to underperform the barbarous relic over the long term and you should know why

CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $131.10, marking a +0.41% move from the previous day.

bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study

bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.

Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins

Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $114.65, marking a -0.73% move from the previous day.

Daniel Laboe headshot

Bulls & Bears Battle It Out In Big Tech

Yields are on the rise and valuation-propelled tech is getting deflated.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day

Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bear of the Day: CRISPR Therapeutics (CRSP)

Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $168.81 in the latest trading session, marking a +0.61% move from the prior day.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates

Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.

Neena Mishra headshot

A Deep Dive into ARK ETFs

We highlight the best performing ETFs managed by Cathie Wood

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why

CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.

Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.